PACB vs. CRSP
Compare and contrast key facts about Pacific Biosciences of California, Inc. (PACB) and CRISPR Therapeutics AG (CRSP).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: PACB or CRSP.
Correlation
The correlation between PACB and CRSP is 0.42, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.
Performance
PACB vs. CRSP - Performance Comparison
Key characteristics
PACB:
-0.54
CRSP:
-0.96
PACB:
-0.34
CRSP:
-1.54
PACB:
0.96
CRSP:
0.84
PACB:
-0.67
CRSP:
-0.59
PACB:
-1.25
CRSP:
-1.89
PACB:
52.12%
CRSP:
26.42%
PACB:
120.30%
CRSP:
51.79%
PACB:
-97.79%
CRSP:
-84.22%
PACB:
-97.52%
CRSP:
-83.72%
Fundamentals
PACB:
$378.27M
CRSP:
$2.93B
PACB:
-$1.59
CRSP:
-$4.34
PACB:
-0.17
CRSP:
-0.21
PACB:
$115.20M
CRSP:
$36.12M
PACB:
$26.00M
CRSP:
-$32.01M
PACB:
-$319.24M
CRSP:
-$311.55M
Returns By Period
In the year-to-date period, PACB achieves a -30.60% return, which is significantly lower than CRSP's -13.14% return.
PACB
-30.60%
-3.42%
-22.56%
-62.76%
-13.73%
-14.09%
CRSP
-13.14%
-19.15%
-25.20%
-47.42%
-2.80%
N/A
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
PACB vs. CRSP — Risk-Adjusted Performance Rank
PACB
CRSP
PACB vs. CRSP - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Pacific Biosciences of California, Inc. (PACB) and CRISPR Therapeutics AG (CRSP). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
PACB vs. CRSP - Dividend Comparison
Neither PACB nor CRSP has paid dividends to shareholders.
Drawdowns
PACB vs. CRSP - Drawdown Comparison
The maximum PACB drawdown since its inception was -97.79%, which is greater than CRSP's maximum drawdown of -84.22%. Use the drawdown chart below to compare losses from any high point for PACB and CRSP. For additional features, visit the drawdowns tool.
Volatility
PACB vs. CRSP - Volatility Comparison
Pacific Biosciences of California, Inc. (PACB) has a higher volatility of 20.49% compared to CRISPR Therapeutics AG (CRSP) at 15.51%. This indicates that PACB's price experiences larger fluctuations and is considered to be riskier than CRSP based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Financials
PACB vs. CRSP - Financials Comparison
This section allows you to compare key financial metrics between Pacific Biosciences of California, Inc. and CRISPR Therapeutics AG. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities